| abstract |
Use of conjugated estrogens and medroxyprogesterone acetate in the manufacture of pharmaceutical packages comprising daily dosage units for the treatment or inhibition of menopausal or postmenopausal disorders in a perimenopausal, menopausal or postmenopausal woman who needs it, in which each dosage unit Daily comprises a combination of conjugated estrogens and a daily dose of approximately 1.5 mg of medroxyprogesterone acetate. |